Metformin Shows No Anti-Aging Effects on Human Placenta in Pregnancy Study
Large randomized trial finds metformin doesn't slow placental aging, challenging its potential as anti-aging therapy during pregnancy.
Summary
Researchers investigated whether metformin, a diabetes drug with proposed anti-aging properties, could slow placental aging during pregnancy. Using samples from 105 women in a randomized trial, plus mouse models and lab studies, they found no evidence that metformin affects placental aging markers including telomere length, gene expression, or tissue changes. The findings support metformin's safety for treating gestational diabetes but don't support using it to prevent pregnancy complications.
Detailed Summary
Placental aging is a natural process that accelerates in pregnancy complications like pre-eclampsia and growth restriction. Since metformin has shown anti-aging properties in other contexts through mechanisms like AMPK activation, researchers investigated whether it could slow placental aging and potentially prevent adverse pregnancy outcomes.
The study used three complementary approaches: placental samples from 105 obese women randomized to metformin or placebo during pregnancy (EMPOWaR trial), isolated human trophoblast cells treated with metformin in culture, and pregnant mice given metformin. Researchers measured multiple aging markers including telomere length, DNA methylation patterns, gene expression profiles, and tissue changes like calcification and fibrosis.
Across all three model systems, metformin showed no impact on placental aging. There were no differences in telomere length, methylation-predicted gestational age, expression of aging-related genes, or histological aging markers between metformin-treated and control groups. Even genes classically associated with cellular aging showed no differential expression, and senescence pathways showed no enrichment with metformin treatment.
These findings have important clinical implications. They provide reassurance about metformin's safety for treating gestational diabetes, as the drug neither accelerates nor interferes with normal placental development. However, they also indicate that metformin cannot be recommended for preventing adverse pregnancy outcomes in non-diabetic women, as it doesn't appear to slow the placental aging process associated with these complications.
The research highlights the need for continued investigation into interventions that could genuinely slow placental aging and reduce pregnancy complications, which affect over 15% of pregnancies globally and represent urgent health priorities worldwide.
Key Findings
- Metformin showed no effect on placental telomere length or methylation-predicted gestational age
- No differences in aging-related gene expression between metformin and control groups
- Histological markers of aging (calcification, fibrosis) unchanged by metformin treatment
- Results consistent across human trial, cell culture, and mouse model systems
- Findings support metformin safety but not efficacy for preventing pregnancy complications
Methodology
Randomized controlled trial with 105 placental samples, complemented by isolated human trophoblast cell culture experiments and mouse model studies. Multiple aging markers assessed including telomere length, gene expression, DNA methylation, and histological changes.
Study Limitations
Study focused on obese women which may limit generalizability. Mouse model used different dosing regimen than humans. Some aging markers may require longer exposure periods to detect effects.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.